Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 48

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 48
---
241 under the November 2024 Keystone Purchase Agreement. Additionally, in January
2025, the Company received net proceeds of $716,694 from the collection of stock subscription receivable, which was reflected as a stock
subscription receivable on December 31, 2024. The Company sought and received a waiver to sell the shares below the applicable minimum
price in the agreement.

During the three months ended June 30, 2025, the Company sold 75,064
common shares of the Company for net proceeds of $481,971 under the November 2024 Keystone Purchase Agreement.

Issuance of Common Stock to Arena Business Solutions Global SPC II, Ltd. (“Arena”) for the Arena ELOC

On February 23, 2024, the Company entered into a common stock purchase agreement (the “Arena Purchase Agreement”) with Arena, pursuant to which we may sell and issue, and Arena is obligated to purchase, up to $25,000,000 of Common Stock. The price of the shares purchased by Arena under the ELOC is 90% of various VWAP and closing price-based formulae, and requires a waiver, should the selling price be below $500.00 per share. As consideration for Arena commitment to purchase shares of Common Stock pursuant to the Arena Purchase Agreement, in May 2024, the Company issued 173 shares of Common Stock to Arena valued at $500,000, which is reflected as deferred offering costs on the accompanying consolidated balance sheet as of June 30, 2025 and December 31, 2024. The Company has sold no shares of Common Stock to Arena under the Arena ELOC during the six months ended June 30, 2025 and 2024.

Sale of Pre-funded Warrants and Common Stock

On February 5, 2025, the Company announced the pricing of a reasonable
best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors
and a single institutional investor, for the purchase and sale of (i) 127,551 shares of its common stock, par value $0.0001 per share
(the “Common Stock”) or common stock equivalents in lieu thereof (the Company sold 15,000 shares of its common stock and 112,551
pre-funded warrants); and (ii) common warrants to purchase up to 127,551 shares of common stock (the “Warrants”), at a combined
public offering price of $39.20